Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer, treatment using tyrosine kinase inhibitors

Figure 7.3. Structure of PD 153035, a tyrosine kinase inhibitor that may be of therapeutic use in the treatment of cancers caused by inappropriate overexpression of EGF-associated tyrosine kinase activity... Figure 7.3. Structure of PD 153035, a tyrosine kinase inhibitor that may be of therapeutic use in the treatment of cancers caused by inappropriate overexpression of EGF-associated tyrosine kinase activity...
AstraZeneca s gefitinib (Iressa) s core structure is a quinazoline. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) indicated for the treatment of cancers. Several other protein kinase inhibitors also used the quinazoline ring as their core structure. They include OSI s erlotinib (Tarceva) and GSK s lapatinib (Tykerb). [Pg.16]

Feng X, Guan H, Kan Y, loannidis S, Peng B, Su M, Wang B, Wang T, Zhang H-J (2007) 4-(3-Aminopyrazole)pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer. WO 2007049041... [Pg.664]

Imatinib is an inhibitor of the protein tyrosine kinase involved with platelet-derived growth factor (Bcr-ABL). A loss of cellular control of this tyrosine kinase has been identified as a key mechanism for malignant cell growth. The ability of imatinib to inhibit Bcr-ABL provides a rationale for its use in the treatment of human cancers such as Philadelphia... [Pg.78]

A number of inhibitors of various tyrosine kinase enzymes are important new cancer drugs sunitinib (Sutent) is used for the treatment of certain kidney and GI cancers imatinib (Glivec) for chronic myeloid leukemia and GI tumours, and lapatinib (Tykerb/Tykerv) for breast and lung cancers. Bortezomib (Velcade), a proteasome inhibitor is used to treat multiple myeloma and is notable for being a boronic acid. [Pg.662]

Fatty acids make the list, especially lauric acid and unsaturated oleic acid. Flavianic acid is a precursor in the preparation of the essential amino acid arginine and the nonessential amino acid tyrosine. Moss (1992) has a chapter about using arginine in the treatment of cancer. Tyrosine interestingly enters the picture as a component of the enzyme tyrosine kinase, the latter in the role of an inhibitor for cancerous stem cells, to be described in Chapter 10. [Pg.105]

See other pages where Cancer, treatment using tyrosine kinase inhibitors is mentioned: [Pg.172]    [Pg.569]    [Pg.1257]    [Pg.469]    [Pg.186]    [Pg.707]    [Pg.109]    [Pg.92]    [Pg.422]    [Pg.569]    [Pg.1257]    [Pg.460]    [Pg.102]    [Pg.2289]    [Pg.127]    [Pg.1473]    [Pg.1619]    [Pg.134]    [Pg.16]    [Pg.51]    [Pg.331]    [Pg.349]    [Pg.102]    [Pg.454]    [Pg.41]    [Pg.399]    [Pg.25]    [Pg.31]    [Pg.400]    [Pg.410]    [Pg.455]    [Pg.190]    [Pg.179]    [Pg.178]    [Pg.1257]    [Pg.149]    [Pg.506]    [Pg.67]    [Pg.1309]    [Pg.1257]    [Pg.218]    [Pg.2375]    [Pg.151]    [Pg.639]    [Pg.607]   
See also in sourсe #XX -- [ Pg.505 , Pg.510 ]



SEARCH



Cancer treatment

Cancer, treatment using

Cancer, treatment using inhibitors

Cancer, treatment using tyrosine kinase receptor inhibitors

Inhibitors use

Kinase cancers

Kinase inhibitors

Kinase, kinases inhibitors

Tyrosine inhibitors

Tyrosine kinases

Tyrosines tyrosine kinase

© 2024 chempedia.info